These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 30394563

  • 1. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J, Rea D, Lipton JH.
    Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
    [Abstract] [Full Text] [Related]

  • 2. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
    Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R.
    Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
    [Abstract] [Full Text] [Related]

  • 3. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J.
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M, Efficace F, Colafigli G, Scalzulli E, Di Prima A, Martelli M, Foà R.
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [Abstract] [Full Text] [Related]

  • 5. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT, Cortes JE, Kantarjian HM.
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [Abstract] [Full Text] [Related]

  • 6. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L, Akard LP.
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [Abstract] [Full Text] [Related]

  • 7. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.
    Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
    [Abstract] [Full Text] [Related]

  • 8. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
    Dulucq S, Mahon FX.
    Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039
    [Abstract] [Full Text] [Related]

  • 9. Nilotinib in the treatment of chronic myeloid leukemia.
    Sacha T, Saglio G.
    Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
    [Abstract] [Full Text] [Related]

  • 10. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

  • 11. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 12. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
    Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM.
    Blood Cancer J; 2023 Apr 24; 13(1):58. PubMed ID: 37088793
    [Abstract] [Full Text] [Related]

  • 13. [Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia].
    Slezáková K, Mistrík M, Bátorová A.
    Vnitr Lek; 2020 Apr 24; 66(4):214-224. PubMed ID: 32972178
    [Abstract] [Full Text] [Related]

  • 14. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon.
    Elias F, Gebran A, Said C, Beker RV, Ammar W.
    J Glob Oncol; 2019 Jun 24; 5():1-7. PubMed ID: 31166826
    [Abstract] [Full Text] [Related]

  • 15. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP.
    Ann Intern Med; 2018 Apr 03; 168(7):461-470. PubMed ID: 29459949
    [Abstract] [Full Text] [Related]

  • 16. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Stockley T, Lipton JH, Leber B, Kim DDH.
    Br J Haematol; 2023 Dec 03; 203(5):781-791. PubMed ID: 37697469
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF, Yang YF, Liu BC, Li WM, Xu N, Liu XL, Jiang Q, Dang HB, Liang LX, Zhang Y, Song YP.
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug 14; 43(8):636-643. PubMed ID: 36709147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.